Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infraction

Catheterization and Cardiovascular Interventions

Volumn 63, Issue 2, 2004, Pages 171-176

  Wang, Huang Joe ^a   Lo, Ping Hang ^a   Lin, Jen Jyh ^a   Lee, Han ^a   Hung, Jui Sung ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute myocardial infarction; Nitroprusside; Percutaneous coronary intervention; Slow no reflow phenomenon

Indexed keywords

NITROPRUSSIDE SODIUM;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY CIRCUMFLEX BRANCH; DOSE RESPONSE; FEMALE; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RIGHT CORONARY ARTERY; SAPHENOUS VEIN GRAFT; ST SEGMENT ELEVATION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITROPRUSSIDE; PROGNOSIS; STATISTICS, NONPARAMETRIC; STENTS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 4744365146     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20149     Document Type: Article

References (27)

1. Klein LW, Kern MJ, Berger P, Sanborn T, Block P, Babb J, Tommaso C, Hodgson JM, Feldman T. Society of Cardiac Angiography and Interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2003;60:194-201.
2. Feld H, Lichstein E, Schachter J, Shani J. Early and late angiographic findings of "no-reflow" phenomenon following direct angioplasty as primary treatment for acute myocardial infarction. Am Heart J 1992;123:782-784.
3. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-580.
4. Kotani J, Nanto S, Mintz GS, Kitakaze M, Ohara T, Morozumi T, Nagata S, Hori M. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation 2002;106:1672-1677.
5. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-662.
6. Ishihara M, Sato S, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, Sakai K. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996;132:959-963.
7. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002;57:444-451.
8. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, O'Neill WW, Safian RD. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996;39:113-118.
9. Kloner RA, Alker KJ. The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the "no reflow" phenomenon during coronary reperfusion. Circulation 1984;70:512-521.
10. Weyrens FJ, Mooney J, Lesser J, Mooney MR. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol 1995;75:849-850.
11. Assali AR, Sdringola S, Ghani M, Denkats AE, Yepes A, Hanna GP, Schroth G, Fujise K, Anderson HV, Smalling RW, Rosales OR. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovac Interv 2000;51:27-31.
12. Rawitscher D, Levin TN, Cohen I, Feldman T. Rapid reversal of no-reflow using abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997;42:187-190.
13. Skelding KA, Goldstein JA, Mehta L, Pica MC, O'Neill WW. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv 2002;57:305-309.
14. Hilllegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001;37:1335-1343.
15. Chesebro JH, Knatteurd G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase-clinical findings through hospital discharge. Circulation 1987;76:142-154.
16. Gibson CM, Cannon CP, Piana RN, Maher KA, Davis SF, Breall JA, et al., for the TIMI 4 group. Relationship of coronary flow to myocardial infarction size: two sample methods to subclassify TIMI flow grades. Circulation 1992;86:I453.
17. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole K, Braunwald E, for the TIMI 4 group. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-888.
18. Abbo KM, Dooris M, Glazier Sue, O'Neill WW, Byrd D, Grines CL, Safian RD. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-782.
19. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, Matsui H, Toki Y, Ito T, Hayakawa T. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202-1209.
20. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T. Clinical implications of "no reflow" phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223-228.
21. Ishihara M, Sato H, Tateishi H, Kawagoe T, Muraoka Y, Yoshimura M. Effects of intraaortic balloon pumping on coronary hemodynamics after coronary angioplasty in patients with acute myocardial infarction. Am Heart J 1992;124:1133-1138.
22. Gavin JB, Maxwell L, Edgar SG. Microvascular involvement in cardiac pathology. J Mol Cell Cardiol 1998;30:2531-2540.
23. Kitakaze M, Hori M. Celluar mechanisms of cardioprotection. In: Sperelakis N, Kurachi Y, Terzic A, Cohen MV, editors. Heart physiology and pathophysiolgy, 4th ed. New York: Academic Press; 2001. p 858-860.
24. Pemberton M, Anderson GL, Barker JH. Characterization of microvascular vasoconstriction following ischemia/reperfusion in skeletal muscle using videomicroscopy. Microsurgery 1996;17:9-16.
25. Wang WZ, Anderson GL, Fleming JT, Peter FW, Franken RJPM, Acland RD, Backer JH. Lack of nitric oxide contributes to vasospasm during ischemia during ischemia/reperfusion injury. Plast Reconstr Surg 1997;99:1099-1108.
26. Fischell TA, Carter AJ, Foster MT, Hempsall K, DeVries J, Kim DH, Kloostra A. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998;45:360-365.
27. Abaci A, Oguzhan A, Eryol NK, Ergin A. Effect of potential confounding factors on thrombolysis in myocardial infarction (TIMI) trial frame count and its reproducibility. Circulation 1999;100:2219-2223.